Rheumatology

Cyltezo Is a Contender for First Interchangeable to Humira, Boehringer Ingelheim Says

April 29th 2021

By Tony Hagen

The results of Voltaire-X could persuade the FDA to authorize automatic substitution of the adalimumab biosimilar Cyltezo for its reference product (Humira), investigators believe.

Toothful or Toothless? Biden's Biosimilar Bills Under the Microscope

April 28th 2021

By Tony Hagen

How much muscle did Congress invest in a pair of bills recently signed by President Biden? The answer may lie in your willingness to believe.

Samsung Bioepis Racks Up More Awards for Its Biosimilar Packaging

April 24th 2021

By Tony Hagen

Medicinal packaging shouldn't remind patients that they have a condition, according to Samsung Bioepis.

Medicines for Europe Panel Tackles Biosimilar Uptake

April 23rd 2021

By Tony Hagen

The European Union is a diverse market with pockets of biosimilar resistance but also cost-saving triumphs, panelists said at the Biosimilar Medicines Virtual Summit 2021.

New Brunswick, Canada, Switches Patients to Biosimilars

April 21st 2021

By Tony Hagen

Following the lead of British Columbia and Alberta, New Brunswick, a heavily forested province located between Nova Scotia and Quebec, hopes to save on biologics.

Study: Investigators Report Superior Adherence, Savings for Biosimilars

April 20th 2021

By Tony Hagen

Weaker persistency and strong adherence were observed among patients taking biosimilar forms of epoetin alfa and infliximab, among others.

British Columbia Switches From Humira to 5 Biosimilar Versions

April 19th 2021

By Tony Hagen

Anticipating roughly $26 million in annual savings, British Columbia's public payer PharmaCare is switching patients away from originator Humira.

New York Medicaid Ramps Up Biosimilar Use

April 15th 2021

By Tony Hagen

New York Medicaid achieved 78% to 94% biosimilar utilization for 4 originator brands during a focused effort in 2019.

Poll: What Is the Best Way to Improve Biosimilar Access?

April 14th 2021

Opinions are diverse on how best to clear the obstructions to biosimilar market entry and patient access.

NORC: Pricing Transparency Could Aid Biosimilar Uptake

April 14th 2021

By Tony Hagen

This is the second of a 2-part series on a study from the independent research center NORC at University of Chicago concerning biosimilar acceptance and uptake.